Relevance Ventures

The firm believes the chronic disease crisis is a structural systems failure, not a medical one, and that the massive shift from treatment to prevention represents a market opportunity. It targets early-growth companies — primarily Series A through C — that make prevention scalable across digital health, financial health, community health, and personal health. This thesis is grounded in the statistic that 90% of US health spending is tied to chronic disease, yet less than 5% of resources go to prevention.

Relevance Ventures is the first independently owned Native American venture firm in the United States. The firm states it invests with a structural obligation to generate returns while addressing systemic inequities in health access and outcomes, treating this not as a branding layer but as an embedded feature of its deal evaluation. Its certification by the TriState Minority Supplier Development Council and its participation in the State Small Business Credit Initiative reflect operational alignment with that identity.

The firm focuses on early-growth venture capital, specifically Series A, B, and C rounds. It invests directly into operating companies rather than through fund-of-funds structures. Its website's contact section invites both founders and institutional allocators to engage, indicating it considers co-investment alongside other venture firms and may accept outside limited partner capital into its vehicles.

Selected disclosed investments include Xsolis, which uses data and automation to reduce friction between healthcare providers and payers; Concert, a healthcare technology company harmonizing evidence, care, and payment for diagnostics and therapeutics; and GenomOncology, which provides infrastructure that transforms fragmented oncology data into clinical decisions. Other named portfolio companies operate in mental healthcare delivery and GERD treatment devices.

In February 2024, the Tennessee Department of Economic and Community Development awarded Relevance Ventures a contract through the State Small Business Credit Initiative, a federal program designed to strengthen small business financing ecosystems. The contract is directed toward deploying capital to underserved entrepreneurs in the state, aligning with the firm's broader mandate to combine financial returns with improved health equity (per Tennessee ECD, February 2024).

The firm's website and strategy materials do not list explicitly excluded sectors. However, its investment activity is concentrated entirely within health-related fields — digital, financial, community, and personal health — with an emphasis on companies that can scale prevention. It does not invest in pure-play biotech drug development, medical devices unconnected to its prevention thesis, or industries outside the intersection of health and technology, though no formal negative screen is published.

The firm does not publicly name its investment committee, managing partners, or individual decision-makers on its website or in available materials. No principal names were captured in the provided sourcing. Allocators conducting due diligence will need to request a meeting directly through the firm's contact channels to understand the leadership team and governance structure.